<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200908048665N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-06-01</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>Effects of extract of Foeniculum vulgare on patients with polycystic ovary syndrome (PCOS)</public_title>
      <acronym></acronym>
      <scientific_title>Effects of extract of Foeniculum vulgare on serum levels of estrogen, progesterone, LH and FSH hormones and miR-499, BMP15 and GDF9 genes expression in granulosa cells of patients with polycystic ovary syndrome (PCOS)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67587</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: In this study, the level of hormones LH, FSH, estrogen, progesterone and the expression level of 499-miR and BMP15 and GDF9 genes in granulosa cells of women with polycystic ovary syndrome as well as two healthy groups and patients without intervention were investigated. The desired measurements were performed before and after the intervention group, but only baseline values were measured in the other two groups. All measurements were among the routine measures for patients presenting with infertility complaints, Randomization description: Individual block randomization was considered by considering fifteen blocks and within each block three groups (A, B, and C) whose order was set randomly. So, finally, the list of 45 people who were assigned to each group was placed in 45 sealed envelopes, with numbers 1 to 45 written on the envelopes, and the study group was recorded inside the envelopes. The arrangement of the groups was done based on the block allocation by the website https://www.sealedenvelope.com, Blinding description: In this study, only the person investigating the results (hormones and expression of desired genes) in the laboratory did not know about the grouping of the patients, but the patients and the researchers were aware of the grouping.</study_design>
      <phase>2-3</phase>
      <hc_freetext>polycystic ovary syndrome (PCOS).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: women with polycystic ovary syndrome (PCOS) treated with fennel extract in the amount of 100 mg twice a day in the form of capsules made by the research group. Intervention 2: Control group: This group was given a placebo in the form of capsules similar to the intervention group, which contained starch, twice a day for 45 days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Row data will be available.

When:
After publication

To whom:
Researchers

Conditions:
For systematic review and meta-analysis.

Where to obtain:
Research deputy at Kurdistan University of Medical Sciences

How to obtain:
Send a request to the research deputy at the University

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rojin Ramezani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran st., Medical Sciences, Razi Alley 6</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6616945457</zip>
        <telephone>+98 87 3361 1017</telephone>
        <email>Rojin.Ramezani@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rojin Ramezani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran St., Medical Sciences, Razi Alley 6</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6616945457</zip>
        <telephone>+98 87 3361 7101</telephone>
        <email>Rojin.Ramezani@gmail.com</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>According to the Adams criteria based on ovarian ultrasound manifestations is to have at least 10 cysts with a diameter of 2-8 mm around the central stroma, densely and in the form of a necklace.
Having Rotterdam diagnosis criteria (menstrual cycle disorder, clinical symptoms, and diagnosis of polycystic ovary in ultrasound diagnosed by a radiology specialist and infertility fellowship).
BMI between 18-22
Age between 20-35 years</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients with Cushing's syndrome and weight-induced amenorrhea
Pituitary disorders
Congenital Adrenal Hyperplasia (CAH)
Prolactinoma
Thyroid disorders
Androgen-secreting tumors
Hypertension
Chronic kidney disease
Alcoholics and smokers
Previous miscarriage
Infertility in their husbands</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: women with polycystic ovary syndrome (PCOS) treated with fennel extract in the amount of 100 mg twice a day in the form of capsules made by the research group.</i_keyword>
      <i_keyword>Control group: This group was given a placebo in the form of capsules similar to the intervention group, which contained starch, twice a day for 45 days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum level of estrogen hormone. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: ELISA test.</prim_outcome>
      <prim_outcome>Serum levels of progesterone. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: ELISA test.</prim_outcome>
      <prim_outcome>FSH serum level. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: ELISA test.</prim_outcome>
      <prim_outcome>LH serum level. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: ELISA test.</prim_outcome>
      <prim_outcome>The expression level of 499-miR. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: Real time PCR.</prim_outcome>
      <prim_outcome>BMP15 gene expression. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: Real time PCR.</prim_outcome>
      <prim_outcome>GDF9 gene expression. Timepoint: Before starting the study and before IVF in three groups and after the intervention in the experimental group (After taking 45 days of ethanol extract of fennel plant). Method of measurement: Real time PCR.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sanandaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-17</approval_date>
        <contact_name>Ethics Committee of Kurdistan University of Medical Sciences</contact_name>
        <contact_address>Sanandaj - Pasdaran Ave Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
